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Abstract
Background: Incisional hernia is a frequent complication in abdominal surgery. This article describes the
development of a prospective randomized clinical trial designed to determine whether watchful waiting is an
acceptable alternative to surgical repair for patients with oligosymptomatic incisional hernia.
Methods/Design: This clinical multicenter trial has been designed to compare watchful waiting and surgical repair
for patients with oligosymptomatic incisional hernia. Participants are randomized to watchful waiting or surgery
and followed up for two years. The primary efficacy endpoint is pain/discomfort during normal activities as a result
of the hernia or hernia repair two years after enrolment, as measured by the hernia-specific Surgical Pain Scales
(SPS). The target sample size of six hundred thirty-six patients was calculated to detect non-inferiority of the
experimental intervention (watchful waiting) in the primary endpoint. Sixteen surgical centers will take part in the
study and have submitted their declaration of commitment giving the estimated number of participating patients
per year. A three-person data safety monitoring board will meet annually to monitor and supervise the trial.
Discussion: To date, we could find no published data on the natural course of incisional hernias. To our
knowledge, watchful waiting has never been compared to standard surgical repair as a treatment option for
incisional hernias. A trial to compare the outcome of the two approaches in patients with oligosymptomatic
incisional hernias is urgently needed to provide data that can facilitate the choice between treatment options. If
watchful waiting was equal to surgical repair, the high costs of surgical repair could be saved. The design for such
a trial is described here.
This multicenter trial will be funded by the German Research Foundation (DFG). The ethics committee of the
Charité has approved the study protocol. Approval has been obtained from ten study sites at time of this
submission. The electronic Case Report Forms have been created. The first patient was to be randomized
November 14
th, 2011. An initiation meeting took place in Berlin January 9
th, 2012.
Trial Registration: ClinicalTrials.gov: NCT01349400
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Incisional hernias occur in 10-20% after elective abdom-
inal incisions and are among the most frequent surgical
complications after laparotomy [1]. Forty-four thousand
incisional hernia repairs were performed in Germany in
2007 [2]. The treatment of incisional hernias thus repre-
sents a large surgical and socioeconomic problem.
A 2009 Danish study addressing the early postopera-
tive outcome reported a major complication rate of
3.5%, an overall morbidity rate of 10.7%, and a mortality
rate of 0.4%. The rehospitalization rate was 11.2% [3].
The long-term outcome of incisional hernia repair is
even more unsatisfactory. Pain persists in 20% of the
patients after hernia repair, and the recurrence rate after
incisional hernia repair remains high despite the devel-
opment of various tension-free techniques (10-50%) [4].
Since incisional hernia repair is not a low-risk operation,
it should be performed only when definitely indicated.
Due to the risk of incarceration, surgery has thus far
been regarded as the only reasonable therapy for
patients with incisional hernia. An incarceration is
defined as an acute retention of the hernia accompanied
by acute severe pain. If not reduced or repaired immedi-
ately, the acute incarcerated hernia leads to impairment
of perfusion of the hernal contents followed by necrosis.
Acute incarceration is a serious complication associated
with high mortality, which is significantly increased if
resection of gangrenous bowel is required [5]. Other
potential factors favoring surgical repair are enlargement
of hernia with the consequence of more difficult repair
and cosmetic reasons.
In fact, there have been no investigations concerning
the actual risk of incarceration or risk factors for incar-
ceration in the total population at risk. Some smaller
studies have reported acute incarceration as the indica-
tion for surgery in 6.0 to 14.6% of incisional hernia
repairs [6-9]. A pre-study in which we prospectively
enrolled all patients with incisional hernia repair dis-
closed an emergency repair rate of 3.2% [10].
In a large prospective randomized trial, Fitzgibbons et
al. demonstrated that the acute incarceration rate is low
in inguinal hernias: 1.8 per 1000 patient-years in mildly
symptomatic men [11]. The percentage of patients with
pain and discomfort interfering with normal activities
did not differ between watchful waiting and surgical
repair after a 2-year follow-up [11]. Delaying surgical
repair was found to have no adverse effect on subse-
quent surgery or the final outcome [12].
Besides medical considerations, health care cost con-
tainment is gaining increasing importance, and the cost-
effectiveness of each procedure has to be taken into
account. A comparison of tension-free repair and watch-
ful waiting in men with minimally symptomatic inguinal
hernias showed $1831 higher mean costs per patient for
tension-free repair after a 2-year follow-up [13].
These randomized controlled trials indicate that
watchful waiting should be considered in men with
asymptomatic or minimally symptomatic inguinal hernia
according to the European Hernia Society Guidelines,
level of evidence 1B [14].
Many surgeons believe that repair of incisional hernias
may become more difficult in the course of time due to
hernia enlargement. Also, there is a lack of data on the
natural course of incisional hernias (enlargement, pain
and discomfort) and the subjective disturbance by the
hernia for cosmetic reasons.
A relevant proportion of incisional hernia patients are
already left without surgical correction, although there
are virtually no data describing or predicting the natural
course. Twenty-two percent of patients presenting with
incisional hernia to outpatient departments of interna-
tionally renowned hernia surgeons received no surgical
treatment. The percentage of patients submitted to sur-
gical repair varied from 50 to 100% for different sur-
geons [15]. Obviously, the treatment of incisional
hernias is not standardized even in experienced hands.
Due to evidence-based data, watchful waiting has
become a reasonable option for minimally symptomatic
inguinal hernias. The potential benefit of a watchful
waiting strategy is the avoidance of a possibly unneces-
sary procedure with all its complications (e.g., wound
infection, mesh infection, bowel injury, ileus, postopera-
tive bleeding, recurrence, chronic postoperative pain)
and cost containment. A randomized controlled trial
comparing watchful waiting and surgical repair in oligo-
symptomatic incisional hernias is urgently needed to
broaden our knowledge regarding the natural course of
incisional hernias and to test watchful waiting as a treat-
ment option.
Methods/Design
Objectives, endpoints and sample size calculation
This clinical trial is designed to investigate the hypoth-
esis that watchful waiting is not inferior to surgical
repair of asymptomatic and oligosymptomatic incisional
hernias in terms of pain and discomfort during normal
activities.
To rule out published or ongoing trials dealing with
the same subject, a literature search was done. Searching
PubMed using the terms “incisional hernia AND watch-
ful waiting” retrieved no matching results. “Incisional
hernia AND randomized trial” retrieved 180 hits, but no
randomized trial comparing watchful waiting to surgical
repair. By searching relevant websites http://www.clini-
caltrials.gov, http://www.actr.org.au, http://www.umin.jp/
ctr/index.htm, http://www.trialregister.nl, http://isrctn.
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surgical repair in incisional hernia could be identified.
The primary efficacy endpoint is pain/discomfort dur-
ing normal activities as a result of the hernia or hernia
repair 2 years after enrolment, as measured by the her-
nia-specific Surgical Pain Scales (SPS). Studies show that
a long term follow up is needed because postoperative
pain may decrease with time [16]. Participants are asked
to rate the average pain during the last 24 hours on a
150 mm visual analog scale varying from “no pain sen-
sation” to “most intense pain imaginable”. The Surgical
Pain Scales were introduced by McCarthy et al. Intra-
class correlation coefficients for SPS were 0.95 and 0.94.
Correlations varying from 0.44 to 0.60 between the
visual analog scales and the bodily pain dimension on
the SF-36 and significant differences between SPS levels
for patients requiring more and less time to resume nor-
mal activities (p = 0.015 to p = 0.002) supported the
validity of the scales [17]. SPS scores are measured at
baseline and at follow-up visits after 6, 12, 18 and 24
months.
The sample size calculation is based on the non-infer-
iority of the experimental intervention. A mean SPS
score of 12.0 with a SD of 12.0 and 12.0 and an expected
mean difference of 0.5 in favor of the surgical interven-
tion group is assumed after a two-year follow-up.
Thus, if both groups have a sample size of 286, a two-
group 0.05 level one-sided t-test will have 80% power to
reject the null hypothesis that watchful waiting is not
equivalent to surgical repair in favor of the alternative
that watchful waiting is not inferior to surgical interven-
tion [18]. This leads to a total sample size of n = 2 ×
286 = 572. Assuming a drop-out rate of about 10%, 636
patients will have to be allocated. Sample size calcula-
tion was done with nQuery 6.0.
The most important secondary endpoint (S1) is the
cost of treatment. Hospitalization costs can be calcu-
lated yearly along the guidelines of the InEK (Institute
for Hospital Reimbursement System) institute. Hospitali-
zation costs in Germany are mapped by the German-
Diagnosis Related Groups-System. Inpatient costs for
each participant (operation; medical staff and nursing
staff on ICU, on IMC and on general ward; medication;
implants; bandaging and other material; catering; infra-
structure; laboratory, radiological, endoscopic and cardi-
ologic diagnostics) will be completely included. Hence,
the exact costs of every patient can be calculated in
Euro [19]. Indirect costs (time off from work) will be
monitored by questionnaire during follow-up.
If the results show a statistical difference in the pri-
mary endpoint, S1 will also be tested for significance
(hierarchical testing). We hypothesize lower costs in the
watchful waiting group, and, if a statistical difference is
found, patient satisfaction with care will be tested as
another secondary endpoint S2. We also hypothesize
superiority of the experimental intervention in the sec-
ondary endpoint S2 because surgery is avoided.
Additional secondary outcomes include pain at rest,
pain during exercise, highest level of pain measured by
the SPS [17]. The impairment of daily activities due to
pain is measured by the German version of the Pain
Disability Index (PDI). The German version of the PDI
revealed objectivity, reliability (Cronbach’s a 0.90) and
factor and construct validity [20]. Principal axis factor
analysis has been used to investigate the underlying
dimensions of the PDI; parallel analysis and scree plot
favored a single-factor solution [21]. The functional sta-
tus and quality of life is measured by the 2
nd German
version of the SF-36 questionnaire. The reliability of the
German version of the SF-36 is satisfactory, the validity
is adequate, and the correlation with another established
quality of life questionnaire (Nottingham-Health-Profile)
is high [22]. Depression/anxiety is assessed by the 3
rd
German version of the Hospital Anxiety and Depression
Scale (HADS-D). Sensitivity and specificity were both
0.80. Reliability is high (Cronbach’s a 0.80) [23]. Post-
operative complications (e.g., postoperative bleeding,
hematoma/seroma, wound infection, mesh infection,
intra-abdominal abscess, ileus, bowel obstruction, enter-
ocutaneous fistula, bowel injury) and mortality are
recorded.
The relative frequency of acute hernia incarceration
(acute incarceration events/duration of hernia) is deter-
mined in the experimental group according to the Fitz-
gibbons’ trial in inguinal hernia [24]. To document the
natural course of the hernia and a potential enlarge-
ment, hernia size is measured by ultrasound in the
watchful waiting group at enrolment and after a 2-year
follow-up. Therefore, ultrasound of the abdominal wall
is performed and the maximum diameter of the hernia
is also determined. The recurrence rate is calculated in
the control group.
A flow chart of the estimated number of screened
patients and the number of randomized and analyzed
patients according to the CONSORT 2010 statement for
reporting parallel group randomized trials [25] is given
in Figure 1.
Inclusion and exclusion criteria
Inclusion and exclusion criteria were chosen broadly to
provide generabilizability. Patients are eligible for enrol-
ment if they meet both of the following criteria: 1) age
≥ 18 years, 2) asymptomatic/oligosymptomatic incisional
hernia (patients with recurrent incisional hernias are
eligible).
Patients are excluded if they meet any one of the fol-
lowing criteria: 1) no hernia detectable on physical
examination, 2) acute incarcerated hernia, 3) emergency
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ing normal activities, 5) local or systemic infection, 6)
ASA score > 3, 7) inability to complete or comprehend
t h ep r e o p e r a t i v eq u e s t i o n n a ire, 8) repair with biologic
prosthesis.
Implementation of the study
All patients presenting to the outpatient clinic with a
possible incisional hernia are screened for trial eligibility.
Those who have no unequivocal contraindications are
scheduled to see the participating surgeon to confirm
that they are candidates for the study. Informed consent
is obtained for participation and randomization after
taking a thorough history, performing a physical exami-
nation and checking for inclusion and exclusion criteria.
Randomization will be done by an electronic randomiza-
tion tool created by the Coordinating Center for Clinical
Studies (KKS Charité). After obtaining the patient’s
informed consent, the site coordinator will log into the
password-protected electronic randomization tool,
which provides stepwise explanations. Randomization
will be stratified by study center, hernia size (< 4 cm vs.
≥ 4 cm) and planned surgical repair (laparoscopic vs.
open).
In primary analysis, adjustment for strata will be per-
formed. We will additionally perform subgroup analyses
within the strata and present the individual 95%-CIs.
Furthermore, strata specific effect size calculations are
planned if necessary.
Considering the lack of a prospective study on inci-
sional hernia repair and the variety of repair techniques,
many different methods can be adopted to enable gener-
alizability and adequate recruitment.
Open incisional hernia repair will be performed with
mesh (non-absorbable or partly absorbable alloplastic
material) or sutures. Laparoscopic repair will be
performed with non-absorbable or partly absorbable
mesh in intraperitoneal onlay position (IPOM). The sur-
geon performing the operation can choose the optimal
approach. Sublay mesh repair with closure of the perito-
neum is recommended for hernias measuring ≥ 3c m .
IPOM, inlay or onlay repair are also permitted. The
mesh should widely overlap the fascial margin (≥ 4c m )
on all sides. In non-mesh repair, either direct suture
repair or the Mayo procedure [26] can be performed.
The type of repair, the type of mesh, the suture material,
the suturing method, and the peritoneal and fascial clo-
sure have to be documented to identify potential differ-
ences by subgroup analysis.
Participants randomized into the watchful waiting
group will receive standardized oral information and
written instructions which, like those described by Fitz-
gibbons et al., will deal with physical activity, diet, pain
and pain medication, constipation management, sexual
activity, hernia warning signs, and symptoms of acute
incarceration [24]. They will be told to consult a physi-
cian immediately if acute symptoms develop. Physical
examinations will be performed during follow-up visits
at 1 month, 12 months and 24 months by a physician.
After 6 and 18 months, participants will also be inter-
viewed regarding potential hernia-related pain or dis-
comfort by a physician or a study nurse. The frequency
and scope of study visits is presented in table 1.
Monitoring and statistical analysis
The Coordinating Center for Clinical Studies (KKS
Charité) deals with project management, monitoring,
and data management including randomization. After
assessing the trial sites for qualification during a pre-
study visit, the monitor will visit them on a regular
basis. Visits will take place at least as follows: prior to
enrolment of the first patient, three times during the
course of the study, and at the time of study comple-
tion. Monitors work according to the Standard Operat-
ing Procedures (SOPs) of the KKS.
The following adverse events (AEs) are monitored
(underlined): A wound infection is defined as a purulent
discharge from the wound or detection of bacteria in
wound samples taken using aseptic technique [27]. An
intra-abdominal abscess must meet a least one of the
following criteria: purulent drainage from a drain which
is placed into the abdomen; organisms isolated from
intra-abdominal aseptically obtained culture; abscess
verified by direct examination during operation or by
radiologic examination [27]. A mesh infection is defined
as a detection of bacteria on the mesh with local signs
of infection (redness, hyperthermia, swelling and pain)
or general signs of infection like fever or tachycardia
without any other reason [28]. Sepsis is recognized clini-
cally as the presence of two or more of the following: 1)
Assessed for eligibility (n=2500) 
Randomized (n=636) 
Excluded (n=1864) 
Not meeting inclusion criteria 
(n=1150) 
Declined to participate (n=714) 
Allocated to surgical repair 
(n=318) 
Received allocated 
intervention (n=313) 
Did not receive allocated 
intervention (n=5) 
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Figure 1 Estimated trial flow of the study.
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heart rate greater than 90 bpm; 3) Respiratory rate
g r e a t e rt h a n2 0b p mo rP a C O 2<3 2m m H g ;4 )W B C
count greater than 12,000 cells/mm
3 or less than 4000
cells/mm
3 and an association with infection confirmed
by culture or strongly suspected [29]. Intestinal injury or
organ injury is defined as the transmural injury or the
intestinal/organ wall. An enterocutaneous fistula is
defined as a direct connection from the intestines to the
skin with discharge of stools through the fistula.
Postoperative bleeding is defined as a bleeding requir-
ing either blood transfusion or reoperation. Pneumonia is
defined as an infection of the lung that can be caused by
nearly any class of organism (bacteria, amoebae, viruses,
fungi, and parasites) known to cause human infections. A
urinary tract infection is an infection of one or more
structures in the urinary system. A deep vein thrombosis
is a blood clot in a major vein that usually develops in
the legs or pelvis. Pulmonary embolism is an obstruction
of a blood vessel in the lungs, usually due to a blood clot.
A bowel obstruction is defined as the necessity to insert a
nasogastric tube longer than 72 h after the operation or
the necessity to reoperate. A recurrent hernia is a hernia
diagnosed by physical examination or ultrasound after
surgical hernia repair.
Other AEs are: vomiting and pain at rest. The follow-
ing severe adverse events (SAEs) are monitored: reo-
peration, rehospitalization, ICU admission, acute
incarceration, death. The principal investigator is
informed about SAEs within 3 days.
An independent Data Safety Monitoring Board
(DSMB) consisting of 3 external experts (2 clinical
experts and 1 statistician) will meet annually to address
patient safety and perform risk-benefit assessments. In
accordance with its standard operating procedures
(SOPs), the DSMB reviews the accumulating data from
the ongoing trial to ensure continued patient safety. The
DSMB assesses study aspects such as progress, integrity,
and design and makes recommendations to the coordi-
nating investigator regarding modification, continuation
or termination of the study.
The primary statistical analyses will be conducted by
the Institute of Biometry and Epidemiology at the Char-
ité using an intention-to-treat (ITT) approach. Interim
analysis is not planned. Additional as-treated analyses
will be performed. Investigators are masked to the
patient’s treatment arm at the time of enrolment. The
statistician will be blinded while performing data
analyses.
Discussion
This article describes the design of a trial comparing
surgical and nonsurgical management of incisional her-
nias. Incisional hernia repair is not a low-risk operation,
and it is associated with a high recurrence rate and a
high percentage of postoperative pain. Treatment of
incisional hernias represents a large surgical and socioe-
conomic problem. Up to now, surgical treatment has
been recommended for incisional hernia patients regard-
less of whether there are any symptoms indicating a
Table 1 Frequency and scope of study visits
Visit Visit 1
(Screening)
Visit 2 (Day
of surgery)
Visit 3 (1
month post
OP)
Visit 4 (6
months post
OP)
Visit 5 (12
months post
OP)
Visit 6 (18
months post
OP)
Visit 7 (24
months post
OP)
Demographics and
baseline clinical data
X
Inclusion/exclusion
criteria
X
Randomization X
Clinical examination X X X X
Ultrasound X X
Pain level (SPS, PDI) X X X X X
Quality of life (SF-36) X X X X X
Mental health (HADS-
D)
X X
Patient satisfaction
(Likert scale)
XX X X X
Surgical intervention X
Postoperative
complications
XX X
AEs/SAEs X X X X X X
Costs of treatment X X X X X X
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tions. No studies have as yet defined the exact indica-
tions for incisional hernia repair or described the
natural course of an incisional hernia, including the risk
of acute incarceration. Randomized controlled trials per-
formed in the past few years have shown that watchful
waiting is a reasonable option for mildly symptomatic
inguinal hernias.
To our knowledge, this is the first study to compare
watchful waiting with surgical repair of oligosympto-
matic incisional hernias in a prospective randomized
setting. The study will provide very useful information
regarding the natural course of incisional hernias and
the rate of incarceration. We hypothesize that pain
intensity during everyday activities does not differ
between the compared groups and that the incarceration
rate is low. If this should be confirmed, it would be jus-
tifiable to apply a watchful waiting strategy for oligo-
symptomatic incisional hernias and to thus avoid the
risks and costs of surgery.
Trial status
AWARE is funded by the German Research Foundation
(DFG; project funding reference number LA 2380/3-1).
Thus adequate financial resources are available to hire
appropriate personnel (e.g., research nurses, project
managers, monitors, and data managers) and cover addi-
tional expenses.
The study protocol has been approved by the Ethics
Committee of the Charité. The trial protocol was regis-
tered http://clinicaltrials.gov/ on May 05, 2011 and was
given a unique number for a worldwide identification of
this trial (identifier: NCT01349400).
All 19 study sites received a study synopsis and signed
the Declaration of Commitment. Participating study
sites are: Charité Campus Benjamin Franklin, Berlin;
Charité Campus Mitte, Berlin; Charité Campus Virchow
Klinikum, Berlin; Universitätsklinikum Heidelberg; Uni-
versitätsklinikum Freiburg; Universitätsklinikum Carl
Gustav Carus Dresden; Medizinische Fakultät Man-
nheim; HELIOS Klinikum Erfurt; HELIOS Klinikum
Schwerin; Klinikum Südstadt Rostock; Johannes Guten-
berg Universität Mainz; Klinikum Augsburg; Universi-
tätsklinikum Bonn; Krankenhaus Sinsheim;
Universitätsklinikum Münster, Diakoniekrankenhaus
Henriettenstiftung Hannover, Ludwig-Maximilians-Uni-
versität München, Unfallkrankenhaus Berlin, Klinikum
rechts der Isar der Technischen Universität München.
This declaration specified the inclusion and exclusion
criteria, and the trial sites used hospital data manage-
ment systems to estimate the annual number of patients
willing to participate. According to these declarations,
949 patients will be enrolled in 36 months. Each center
plans to enroll 5 to 40 patients each year. Non-
university and university medical centers are involved to
increase the generalizability of the study. All participat-
ing centers are familiar with clinical studies. Eight of
them belong to the Chir-Net Germany, a network of
regional surgical centers funded by the Federal Ministry
of Education and Research (BMBF) and devoted to the
development and implementation of multicenter clinical
trials. All study centers have received the final study
protocol. In 10 centers, the approval of the local ethics
committees has been obtained.
The electronic case report forms (eCRFs) and the ran-
domization tool have been completed.
An initiation meeting in Berlin took place in January
9, 2012 to introduce the principal investigators and to
familiarize the study centers with the details of screen-
ing, randomization, surgery, monitoring and follow-up.
The whole study team was present. The first patient was
randomized at Charité Campus Benjamin Franklin
November 14, 2011.
The recruitment period is planned for 36 months
(until October 2014); last-patient-out should be achieved
in November 2016.
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